rituximab
not tagged
['rituximab', 'lyma', 'lymsm', 'cml', 'ritux']
7-year follow up of lyma trial (maintenance rituximab v observation after asct for mcl). os benefit no longer significant (??), and os after relapse in r arm significantly worse than observation. pod24 with very poor prognosis. any ideas why os benefit changed, #lymsm? #17icml 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈